ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a

• Main Authors: Kyung Hee Jung, Mi Kwon Son, Hong Hua Yan, Zhenghuan Fang, Juyoung Kim, Soo Jung Kim, Jung Hee Park, Ji Eun Lee, Young‐Chan Yoon, Myeong Seong Seo, Beom Seok Han, Soyeon Ko, Young Ju Suh, Joo Han Lim, Don‐Haeng Lee, Ziqiang Teo, Jonathan Wei Kiat Wee, Nguan Soon Tan, Soon‐Sun Hong
• Format: Article
• Language: English
• Published: Wiley 2020-08-01
• Series: EMBO Molecular Medicine
• Subjects: acute pancreatitis; ANGPTL4; C5a; macrophage
• Online Access: https://doi.org/10.15252/emmm.201911222
• ISSN: 1757-4676; 1757-4684

Abstract Pancreatitis is the inflammation of the pancreas. However, little is known about the genes associated with pancreatitis severity. Our microarray analysis of pancreatic tissues from mild and severe acute pancreatitis mice models identified angiopoietin‐like 4 (ANGPTL4) as one of the most significantly upregulated genes. Clinically, ANGPTL4 expression was also increased in the serum and pancreatic tissues of pancreatitis patients. The deficiency in ANGPTL4 in mice, either by gene deletion or neutralizing antibody, mitigated pancreatitis‐associated pathological outcomes. Conversely, exogenous ANGPTL4 exacerbated pancreatic injury with elevated cytokine levels and apoptotic cell death. High ANGPTL4 enhanced macrophage activation and infiltration into the pancreas, which increased complement component 5a (C5a) level through PI3K/AKT signaling. The activation of the C5a receptor led to hypercytokinemia that accelerated acinar cell damage and furthered pancreatitis. Indeed, C5a neutralizing antibody decreased inflammatory response in LPS‐activated macrophages and alleviated pancreatitis severity. In agreement, there was a significant positive correlation between C5a and ANGPTL4 levels in pancreatitis patients. Taken together, our study suggests that targeting ANGPTL4 is a potential strategy for the treatment of pancreatitis.